Sareum Holdings plc (Sareum) is a United Kingdom-based holding company. The Company is a cancer drug discovery company. The Company, along with its subsidiaries, is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company focuses on developing therapies for cancer and auto-immune diseases. In August 2011, the most promising lead molecule from this programme was declared a candidate for pre-clinical development. Sareum Kinase Inhibitor Library (SKIL) is Sareum�s drug discovery technology platform that has produced the Company�s Aurora, VEGFR-3, ALK, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against additional kinase and other targets.